Enduring reversal of neuropathic pain by a single intrathecal injection of adenosine 2A receptor agonists: a novel therapy for neuropathic pain
LC Loram, JA Harrison, EM Sloane… - Journal of …, 2009 - Soc Neuroscience
LC Loram, JA Harrison, EM Sloane, MR Hutchinson, P Sholar, FR Taylor, D Berkelhammer…
Journal of Neuroscience, 2009•Soc NeurosciencePrevious studies of peripheral immune cells have documented that activation of adenosine
2A receptors (A2ARs) decrease proinflammatory cytokine release and increase release of
the potent anti-inflammatory cytokine, interleukin-10 (IL-10). Given the growing literature
supporting that glial proinflammatory cytokines importantly contribute to neuropathic pain
and that IL-10 can suppress such pain, we evaluated the effects of intrathecally administered
A2AR agonists on neuropathic pain using the chronic constriction injury (CCI) model. A …
2A receptors (A2ARs) decrease proinflammatory cytokine release and increase release of
the potent anti-inflammatory cytokine, interleukin-10 (IL-10). Given the growing literature
supporting that glial proinflammatory cytokines importantly contribute to neuropathic pain
and that IL-10 can suppress such pain, we evaluated the effects of intrathecally administered
A2AR agonists on neuropathic pain using the chronic constriction injury (CCI) model. A …
Previous studies of peripheral immune cells have documented that activation of adenosine 2A receptors (A2ARs) decrease proinflammatory cytokine release and increase release of the potent anti-inflammatory cytokine, interleukin-10 (IL-10). Given the growing literature supporting that glial proinflammatory cytokines importantly contribute to neuropathic pain and that IL-10 can suppress such pain, we evaluated the effects of intrathecally administered A2AR agonists on neuropathic pain using the chronic constriction injury (CCI) model. A single intrathecal injection of the A2AR agonists 4-(3-(6-amino-9-(5-cyclopropylcarbamoyl-3,4-dihydroxytetrahydrofuran-2-yl)-9H-purin-2-yl)prop-2-ynyl)piperidine-1-carboxylic acid methyl ester (ATL313) or 2-p-(2-carboxyethyl)phenethylamino-5′-N-ethylcarboxamido adenosine HCl (CGS21680), 10–14 d after CCI versus sham surgery, produced a long-duration reversal of mechanical allodynia and thermal hyperalgesia for at least 4 weeks. Neither drug altered the nociceptive responses of sham-operated controls. An A2AR antagonist [ZM241385 (4-(2-[7-amino-2-(2-furyl)(1,2,4)triazolo(2,3-a)(1,3,5)triazin-5-ylamino]ethyl)phenol)] coadministered intrathecally with ATL313 abolished the action of ATL313 in rats with neuropathy-induced allodynia but had no effect on allodynia in the absence of the A2AR agonist. ATL313 attenuated CCI-induced upregulation of spinal cord activation markers for microglia and astrocytes in the L4–L6 spinal cord segments both 1 and 4 weeks after a single intrathecal ATL313 administration. Neutralizing IL-10 antibodies administered intrathecally transiently abolished the effect of ATL313 on neuropathic pain. In addition, IL-10 mRNA was significantly elevated in the CSF cells collected from the lumbar region. Activation of A2ARs after intrathecal administration may be a novel, therapeutic approach for the treatment of neuropathic pain by increasing IL-10 in the immunocompetent cells of the CNS.
Soc Neuroscience